Avecho Biotechnology Halts Trading Pending Phase III Trial Results
Key points
- Trading in AVE shares halted at company's request
- Pending announcement on Phase III trial for CBD TPM capsule
- Expected announcement before June 24, 2026
- Halt to remain until announcement release or market opening
Full summary
Avecho Biotechnology Limited (ASX: AVE) has requested a trading halt on its shares to manage its continuous disclosure obligations. The halt is in place pending the release of an announcement regarding the outcome of the interim analysis for the company's Phase III trial evaluating its proprietary cannabidiol (CBD) TPM capsule for insomnia. The company expects to make the announcement before the commencement of normal trading on Wednesday, 24 June 2026.
Summary generated by a large language model. Please interpret with care.